150 related articles for article (PubMed ID: 20733100)
1. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.
Ferreira-González I; Marsal JR; Ribera A; Permanyer-Miralda G; García-Del Blanco B; Martí G; Cascant P; Martín-Yuste V; Brugaletta S; Sabaté M; Alfonso F; Capote ML; De La Torre JM; Ruíz-Lera M; Sanmiguel D; Cárdenas M; Pujol B; Baz JA; Iñiguez A; Trillo R; González-Béjar O; Casanova J; Sánchez-Gila J; García-Dorado D
Circulation; 2010 Sep; 122(10):1017-25. PubMed ID: 20733100
[TBL] [Abstract][Full Text] [Related]
2. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year.
Ferreira-González I; Marsal JR; Ribera A; Permanyer-Miralda G; García-Del Blanco B; Martí G; Cascant P; Masotti-Centol M; Carrillo X; Mauri J; Batalla N; Larrousse E; Martín E; Serra A; Rumoroso JR; Ruiz-Salmerón R; de la Torre JM; Cequier A; Gómez-Hospital JA; Alfonso F; Martín-Yuste V; Sabatè M; García-Dorado D
J Am Coll Cardiol; 2012 Oct; 60(15):1333-9. PubMed ID: 22999716
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
[TBL] [Abstract][Full Text] [Related]
4. Moderate-severe renal insufficiency is a risk factor for sirolimus-eluting stent thrombosis. The RIFT study.
Zhu ZB; Zhang RY; Zhang Q; Zhang JS; Hu J; Yang ZK; Shen WF
Cardiology; 2009; 112(3):191-9. PubMed ID: 18682662
[TBL] [Abstract][Full Text] [Related]
5. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation.
Roy P; Bonello L; Torguson R; de Labriolle A; Lemesle G; Slottow TL; Steinberg DH; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2008 Dec; 102(12):1614-7. PubMed ID: 19064014
[TBL] [Abstract][Full Text] [Related]
6. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
Migliorini A; Valenti R; Marcucci R; Parodi G; Giuliani G; Buonamici P; Cerisano G; Carrabba N; Gensini GF; Abbate R; Antoniucci D
Circulation; 2009 Dec; 120(22):2214-21. PubMed ID: 19917884
[TBL] [Abstract][Full Text] [Related]
7. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations.
Moussa ID; Colombo A
Catheter Cardiovasc Interv; 2009 Dec; 74(7):1047-54. PubMed ID: 19626692
[TBL] [Abstract][Full Text] [Related]
9. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
Buonamici P; Marcucci R; Migliorini A; Gensini GF; Santini A; Paniccia R; Moschi G; Gori AM; Abbate R; Antoniucci D
J Am Coll Cardiol; 2007 Jun; 49(24):2312-7. PubMed ID: 17572245
[TBL] [Abstract][Full Text] [Related]
10. Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel.
Pasceri V; Patti G; Pristipino C; Pelliccia F; Irini D; Varveri A; Roncella A; Di Sciascio G; Speciale G
Catheter Cardiovasc Interv; 2010 May; 75(6):936-42. PubMed ID: 20146326
[TBL] [Abstract][Full Text] [Related]
11. Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Tada T; Natsuaki M; Morimoto T; Furukawa Y; Nakagawa Y; Byrne RA; Kastrati A; Kadota K; Iwabuchi M; Shizuta S; Tazaki J; Shiomi H; Abe M; Ehara N; Mizoguchi T; Mitsuoka H; Inada T; Araki M; Kaburagi S; Taniguchi R; Eizawa H; Nakano A; Suwa S; Takizawa A; Nohara R; Fujiwara H; Mitsudo K; Nobuyoshi M; Kita T; Kimura T;
Circ Cardiovasc Interv; 2012 Jun; 5(3):381-91. PubMed ID: 22619260
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
13. Noncardiac surgery and bleeding after percutaneous coronary intervention.
To AC; Armstrong G; Zeng I; Webster MW
Circ Cardiovasc Interv; 2009 Jun; 2(3):213-21. PubMed ID: 20031718
[TBL] [Abstract][Full Text] [Related]
14. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
[TBL] [Abstract][Full Text] [Related]
15. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Aronow HD; Steinhubl SR; Brennan DM; Berger PB; Topol EJ;
Am Heart J; 2009 Feb; 157(2):369-74. PubMed ID: 19185647
[TBL] [Abstract][Full Text] [Related]
16. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.
Tavassoli N; Voisin S; Carrie D; Lapeyre-Mestre M; Galinier M; Montastruc JL; Pathak A
Am J Cardiovasc Drugs; 2010; 10(1):29-35. PubMed ID: 20104932
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database.
Petersen JL; Barron JJ; Hammill BG; Cziraky MJ; Anstrom KJ; Wahl PM; Eisenstein EL; Krucoff MW; Califf RM; Schulman KA; Curtis LH
Am Heart J; 2010 Mar; 159(3):462-470.e1. PubMed ID: 20211310
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation.
Rossini R; Capodanno D; Lettieri C; Musumeci G; Nijaradze T; Romano M; Lortkipanidze N; Cicorella N; Biondi Zoccai G; Sirbu V; Izzo A; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
Am J Cardiol; 2011 Jan; 107(2):186-94. PubMed ID: 21211596
[TBL] [Abstract][Full Text] [Related]
19. Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation.
Latib A; Morici N; Cosgrave J; Airoldi F; Godino C; Brambilla N; Chieffo A; Bonizzoni E; Carlino M; Bedogni F; Montorfano M; Sangiorgi GM; Briguori C; Colombo A
Am J Cardiol; 2008 Dec; 102(11):1477-81. PubMed ID: 19026299
[TBL] [Abstract][Full Text] [Related]
20. Reasonable duration of Clopidogrel use after drug-eluting stent implantation in Korean patients.
Shin DH; Chae IH; Youn TJ; Cho SI; Kwon DA; Suh JW; Chang HJ; Cho YS; Chung WY; Choi YJ; Gwon HC; Han KR; Choi DJ
Am J Cardiol; 2009 Dec; 104(12):1668-73. PubMed ID: 19962472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
